Recent Updates
Recently added Catalysts
ETON Positive Sentiment Score: 70/100

Eton Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Wednesday, August 23, 2023 2 min read
Key Takeaway: Eton Pharmaceuticals, a company dedicated to developing treatments for rare diseases, will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference in New York City on September 13, 2023. CEO Sean Brynjelsen will be the speaker, emphasizing Eton's commitment to innovation in the pharmaceutical industry. The company currently offers several products for rare diseases and has multiple candidates in late-stage development, showcasing its active role in addressing unmet medical needs.

Market Sentiment Analysis

POSITIVE FACTORS

  • Eton Pharmaceuticals is presenting at a notable investment conference, highlighting its visibility in the market.
  • The company has a strong focus on developing treatments for rare diseases, demonstrating a commitment to addressing unmet medical needs.
  • Eton has multiple products already commercialized and additional candidates in late-stage development, indicating growth potential.

Full Press Release Details

DEER PARK, Ill., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that Sean Brynjelsen, Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference in New York City as follows:
Date: Wednesday, September 13, 2023
Time: 9:00am ET
To schedule a 1x1 meeting with the Company, please contact Corporate Access at H.C. Wainwright.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing, acquiring, and commercializing innovative products to address unmet needs in patients suffering from rare diseases. The Company currently has three commercial rare disease products, ALKINDI SPRINKLE® for the treatment of pediatric adrenocortical insufficiency, Carglumic Acid for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency, and Betaine Anhydrous for the treatment of homocystinuria. The Company has four additional product candidates in late-stage development: dehydrated alcohol injection, which has received Orphan Drug Designation for the treatment of methanol poisoning, ZENEO® hydrocortisone autoinjector for the treatment of adrenal crisis, ET-400 for the treatment of adrenocortical insufficiency, and ET-600 for the treatment of diabetes insipidus. For more information, please visit our website at www.etonpharma.com.
Lisa M. Wilson, In-Site Communications, Inc.
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals.

Frequently Asked Questions

When is Eton Pharmaceuticals presenting at the conference?

Eton Pharmaceuticals will present on September 13, 2023, at 9:00 am ET.

What products does Eton Pharmaceuticals have for rare diseases?

Eton offers ALKINDI SPRINKLE®, Carglumic Acid, and Betaine Anhydrous for rare diseases.

What are Eton Pharmaceuticals' late-stage product candidates?

Late-stage candidates include dehydrated alcohol injection and ZENEO® autoinjector.

How can I schedule a meeting with Eton Pharmaceuticals?

To schedule a meeting, contact Corporate Access at H.C. Wainwright.

What is Eton Pharmaceuticals' focus?

Eton focuses on developing treatments for rare diseases and unmet patient needs.

Tags: ETON Viatris Investor Conferences Healthcare Eton Pharmaceuticals rare diseases H.C. Wainwright investment conference
Last updated: Aug 23, 2023